1 – 50 of 169
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
(
- Contribution to journal › Article
-
Mark
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders : An International, Multicenter Study
(
- Contribution to journal › Article
-
Mark
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
2024) In JAMA(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's disease
2024) In bioRxiv : the preprint server for biology(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
(
- Contribution to journal › Article
-
Mark
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
(
- Contribution to journal › Article
-
Mark
Divergent functional connectivity changes associated with white matter hyperintensities
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
(
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests
2024) In Nature Medicine(
- Contribution to journal › Article
-
Mark
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
(
- Contribution to journal › Article
-
Mark
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
2024) In Nature Aging(
- Contribution to journal › Article
-
Mark
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
(
- Contribution to journal › Article
-
Mark
Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation
(
- Contribution to journal › Article
-
Mark
Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
(
- Contribution to journal › Article
-
Mark
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
(
- Contribution to journal › Article
- 2023
-
Mark
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
(
- Contribution to journal › Article
-
Mark
Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
(
- Contribution to journal › Article
-
Mark
Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
(
- Contribution to journal › Article
-
Mark
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The genetic regulation of protein expression in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
(
- Contribution to journal › Article